Company news

Emyria Ltd news in 2024

Emyria Ltd's news releases, calls and decks from 2024, newest first.

View company

Emyria Secures $2.525M in Strongly Supported Placement

November 26, 2024

Response to ASX Price Query

November 12, 2024

Emyria & UWA Partner to License Novel Serotonin Therapies

October 30, 2024

September 2024 Quarterly Activities Report and Appendix 4C

October 29, 2024

Emyria Gains Ethics Endorsement for Psilocybin Program

October 27, 2024

Emyria Shares Interim Success in PTSD Treatment Program

September 2, 2024

Appendix 4E & Annual Report for the Year Ended 30 June 2024

August 30, 2024

June 2024 Quarterly Activities Report and Appendix 4C

July 29, 2024

Emyria, UWA Secure $499K Grant for MDMA Analogue Program

June 30, 2024

Empax Centre Selected As Key Site In Global PTSD Study

June 19, 2024

March 2024 Quarterly Activities Report and Appendix 4C

April 25, 2024

Emyria Receives Bids of $2.3M to Expand Clinical Services

April 23, 2024

Emyria opens Empax Centre to target care gaps in resistant PTSD

April 10, 2024

Emyria Opens Empax Centre to Advance Mental Health Care

April 9, 2024

Emyria Expands Specialist AP Team - First Female for MDMA-AT

April 4, 2024

Emyria, Reach Wellness Enter MDMA-AT Research Agreement

April 2, 2024

Response to ASX Aware Query

March 12, 2024

December 2023 Quarterly Activities Report and Appendix 4C

January 30, 2024

Emyria Receives $2.5M R&D Tax Incentive Refund

January 14, 2024

Emyria Specialist Granted Authorised Prescriber Status

January 9, 2024

Decks in 2024